Beyond the Science: How CEOs and Investors Should Evaluate Emerging Therapeutic Platforms

Executive Summary Every biotechnology platform eventually reaches the same inflection point. The science appears compelling. Preclinical data generate enthusiasm. Investors take notice. Management begins discussing platform expansion, multiple indications, and long-term valuation. At that stage, the most important question is no longer scientific. It becomes strategic. Biotechnology history is filled with innovative mechanisms supported by convincing laboratory data that ultimately failed to become successful medicines. In many cases, the biology…